This ambitious anti-TB campaign, as part of IOCL’s CSR, aims to ensure early identification of presumptive TB and prompt diagnosis using high-sensitivity diagnostic tests at the doorstep
The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunization during public health emergencies and pandemics
The company has plans to launch this Vaccine by the end of 2023 after completing the required field studies and obtaining regulatory approvals
For anaemia control in children (0-19 years) & resolves for Call to Action in this direction
A committee of two Joint Drugs Controllers has been constituted at CDSCO to monitor the process of inspection, reporting, and subsequent action to ensure compliance to the Drugs & Cosmetics Act, 1940
Mock drills are being conducted across the country to review the preparedness for management of COVID-19
Yonghe as the CDMO partner will provide production process development and cGMP manufacturing services for Ablaze
WHO made a strong recommendation for nirmatrelvir and ritonavir for mild and moderate COVID-19 patients at highest risk of hospital admission
Subscribe To Our Newsletter & Stay Updated